BIOSENSOR FOR RAPID SCREENING OF GALACTOSEMIA

用于快速筛查半乳糖血症的生物传感器

• 批准号: 2422592
• 负责人: CHUNG Y WANG
• 金额: $ 9.45万
• 依托单位: PROTEIN SOLUTIONS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 1998-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2422592
• 关键词: adenosine triphosphate; bioluminescence; biosensor device; carbohydrates; diagnosis design /evaluation; galactokinase; galactose; galactosemias; luciferin monooxygenase; metabolism disorder diagnosis; method development; urinalysis

Newborns are regularly screened for inborn errors of metabolism during their first days of life. Typical screenings target galactosemia, phenylketonuria, maple syrup urine disease, and homocystinuria. These screenings require that a blood sample be drawn and sent to a clinical chemistry lab with definitive results often not being available for three to four days. This has the potential to delay and sometimes eliminate the possibility for patient compliance with doctor prescribed positive intervention. This research is designed to demonstrate the feasibility of detecting clinically relevant amounts of galactose (an indicator of galactosemia) in urine using a disposable dipstick-type of biosensor based upon ATP fueled and luciferase catalyzed bioluminescence. The quantitative indication from the biosensor is presented as a spatial distribution of light which can be directly determined by visual analysis. Future development will broaden the range of analytes detected and extend the analyses to blood. Such a method for point of care screening for galactose and many other biomolecules linked to inborn errors of metabolism could significantly reduce the incidence of retardation and delayed development by offering simple, accurate, rapid and less costly analyses which will increase the extent of screening and compliance. PROPOSED COMMERCIAL APPLICATION: A need exists for simple, inexpensive, rapid and definitive analyses of numerous biochemicals whose absence or presence may lead to inborn errors of metabolism. Ideally, such analyses can be made with disposable biosensors at the point of care.

定期筛选新生儿，以获取本生的新陈代谢错误 他们生命的第一天。典型的筛选目标半乳糖血症， 苯酮尿症，枫糖浆尿液疾病和同囊尿症。这些 筛查需要抽取血液样本并发送到临床 具有确定结果的化学实验室通常无法获得三个 到四天。这有可能延迟，有时消除 患者遵守医生处方正阳性的可能性 干涉。这项研究旨在证明 检测临床相关量的半乳糖（指标 使用基于生物传感器的一次性尺型在尿液中的半乳糖血症） ATP燃料和荧光素酶催化生物发光。定量 生物传感器的指示表示为作为空间分布 可以通过视觉分析直接确定的光。未来 开发将扩大检测到的分析物的范围并扩展 分析血液。这种用于半乳糖的护理点筛选方法 以及与天生新陈代谢错误有关的许多其他生物分子可能 显着降低延迟和发育延迟的发生率 通过提供简单，准确，快速且成本较低的分析，这将 增加筛查和合规性的程度。 拟议的商业应用： 需要简单，廉价，快速和确定的分析 众多缺乏或存在的生化物可能会导致先天错误 代谢。理想情况下，可以通过一次性进行此类分析 生物传感器在护理点。